1. Home
  2. TALK vs URGN Comparison

TALK vs URGN Comparison

Compare TALK & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TALK
  • URGN
  • Stock Information
  • Founded
  • TALK 2012
  • URGN 2004
  • Country
  • TALK United States
  • URGN United States
  • Employees
  • TALK N/A
  • URGN N/A
  • Industry
  • TALK Medical/Nursing Services
  • URGN Biotechnology: Pharmaceutical Preparations
  • Sector
  • TALK Health Care
  • URGN Health Care
  • Exchange
  • TALK Nasdaq
  • URGN Nasdaq
  • Market Cap
  • TALK 576.9M
  • URGN 547.1M
  • IPO Year
  • TALK N/A
  • URGN 2017
  • Fundamental
  • Price
  • TALK $3.04
  • URGN $11.19
  • Analyst Decision
  • TALK Hold
  • URGN Strong Buy
  • Analyst Count
  • TALK 2
  • URGN 5
  • Target Price
  • TALK $3.00
  • URGN $44.50
  • AVG Volume (30 Days)
  • TALK 2.5M
  • URGN 456.4K
  • Earning Date
  • TALK 10-29-2024
  • URGN 11-06-2024
  • Dividend Yield
  • TALK N/A
  • URGN N/A
  • EPS Growth
  • TALK N/A
  • URGN N/A
  • EPS
  • TALK N/A
  • URGN N/A
  • Revenue
  • TALK $181,291,000.00
  • URGN $89,363,000.00
  • Revenue This Year
  • TALK $28.25
  • URGN $14.43
  • Revenue Next Year
  • TALK $22.51
  • URGN $44.44
  • P/E Ratio
  • TALK N/A
  • URGN N/A
  • Revenue Growth
  • TALK 31.50
  • URGN 15.64
  • 52 Week Low
  • TALK $1.60
  • URGN $10.60
  • 52 Week High
  • TALK $3.92
  • URGN $20.70
  • Technical
  • Relative Strength Index (RSI)
  • TALK 53.25
  • URGN 35.94
  • Support Level
  • TALK $3.20
  • URGN $11.93
  • Resistance Level
  • TALK $3.59
  • URGN $12.78
  • Average True Range (ATR)
  • TALK 0.22
  • URGN 0.71
  • MACD
  • TALK -0.03
  • URGN -0.05
  • Stochastic Oscillator
  • TALK 43.30
  • URGN 1.36

About TALK Talkspace Inc.

Talkspace Inc is a behavioral healthcare company offering access to licensed therapists, psychologists, and psychiatrists through its technology platform. It serves clients including health plans, enterprises, and individual subscribers. Therapists address various mental health conditions, while psychiatrists cater to a higher acuity demographic. Revenue primarily stems from payor and direct-to-enterprise clients, with contracts lasting one to three years. The majority of the Company's operations and revenues are based in the United States.

About URGN UroGen Pharma Ltd.

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in innovative solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.

Share on Social Networks: